HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2021